Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283618 | 0.93 | CHRM3 (0.34) | CHRM3BCHEHCRTR1HCRTR2 | |
| SCHEMBL13705254 | 0.92 | HPGDS (0.36) | USP30HPGDSACKR3APLNRPARP1 | |
| SCHEMBL13705306 | 0.91 | HPGDS (0.35) | USP30HPGDSACKR3APLNRPARP1 | |
| SCHEMBL13705256 | 0.89 | EGFR (0.35) | USP30HPGDSACKR3APLNRPARP1 | |
| SCHEMBL13705261 | 0.89 | HPGDS (0.34) | USP30HPGDSACKR3APLNRPARP1 | |
| SCHEMBL13705262 | 0.88 | HPGDS (0.33) | USP30HPGDSACKR3APLNRHCRTR1 | |
| SCHEMBL13705145 | 0.86 | ABHD6 (0.42) | USP30HPGDSPARP1 | |
| SCHEMBL13705257 | 0.86 | USP30 (0.34) | USP30HPGDSACKR3APLNRPARP1 | |
| SCHEMBL13705312 | 0.85 | PRMT5 (0.36) | USP30HPGDSPARP1KDM1A | |
| SCHEMBL13705315 | 0.85 | USP30 (0.36) | USP30HPGDSACKR3APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP30 3128/4885P2RY12 2069/4885HPGDS 1198/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | USP30 3128/4885P2RY12 2069/4885HPGDS 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.